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licenses/by-nc-nd/4.0impaired left ventricular ejection fraction, treatment with implantable cardioverter-defibrillator (ICD)
has been shown to improve survival and guidelines recommend their use for primary prevention of
sudden cardiac death. Experts disagree regarding the validity of decade-old trial results as the basis
for this recommendation, therefore, reconsideration of prophylactic ICD treatment is needed.
EU-CERT-ICD, DANISH-ICD and DO-IT: In order to update the evidence on prophylactic ICD
treatment, several prospective studies are underway in Europe. The prospective EU-CERT-ICD
cohort study (NCT 02064192) is enrolling 2500 patients and compares patients undergoing first ICD
implantation with controls with an earlier clinical decision to go without ICD implantation strictly
unrelated to the study. The DANISH ICD study (NCT 00542945) has randomized 1000 patients with
dilated cardiomyopathy and an LVEF ≤35% (1:1 ICD implantation vs. control). The prospective
DO-IT multicenter registry will include 1500 ICD patients in multiple Dutch high-volume
implanting centers. Due to the widespread use of ICD therapy, new randomized trials seem not
straightforward to envisage in many countries.
Conclusion: The above described ICD studies will provide additional evidence regarding the
effectiveness of primary prophylactic ICDs in Europe and may have an impact on ICD treatment
guidelines. They could also help to design randomized trials in low risk patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
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In patients with impaired left ventricular ejection fraction
(LVEF, ≤35%), treatment with an implantable
cardioverter-defibrillator (ICD) for primary prevention of
sudden cardiac death (SCD) has become a guideline
indication more than 10 years ago. This recommendation
was largely based on two landmark trials, the MulticenterC, European Society of Cardiology; ICD, implantable
or; LVEF, left ventricular ejection fraction; NYHA,
ciation; MADIT-II, Multicenter Automatic Defibril-
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[1] and the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT) [2], showing a survival benefit of 23% to 31%
of ICD recipients compared to patients without ICD
treatment. Participants of these studies were enrolled
between 1997 and 2003. Therefore, experts disagree
regarding the validity of decade-old trial results as the
basis for this recommendation, and a reconsideration of
primary prophylactic ICD treatment is needed. First, clinical
decision-making based on left ventricular ejection fraction
(LVEF) as the only factor must over-simplify the stratifica-
tion of patients at risk. Second, important outcomes such as
overall mortality and appropriate shock rate have decreased
over the years [3], after many improvements of pharmaceu-
tical and interventional treatment options of coronary artery
disease and heart failure having emerged in between [4,5].
Furthermore, improved ICD programming has led toess article under the CC BY-NC-ND license (http://creativecommons.org/
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inappropriate ICD therapies, especially of anti-tachycardia
pacing therapies [6]. In Europe, low annual mortality rates of
5% [7,8] and annual appropriate shock rates of 4–5% are
typical [7]. Third, important subgroups such as women [7,9]
or elderly patients [10] have been described to potentially
exhibit a lower than average benefit from the ICD. In the
current overview, ongoing European ICD studies are
presented, with particular focus on the EU-CERT-ICD risk
stratification study.Ongoing prospective ICD studies in Europe
Several prospective studies are currently enrolling
patients in Europe. One of them is a randomized ICD trial
in patients with dilated cardiomyopathy (DANISH-ICD,
NCT00542945), the other two are prospectively designed
cohort studies for the purpose of improved risk stratification
(EU-CERT-ICD and DO-IT).
European Comparative Effectiveness Research to assess the
use of primary prophylactic Implantable Cardioverter
Defibrillators (EU-CERT-ICD)
The EUropean Comparative Effectiveness Research to
assess the use of primary prophylacTic Implantable
Cardioverter Defibrillators (EU-CERT-ICD, NCT02064192)
project is funded by the European Commission and is
conducted in 26 academic institutions in 14 European
countries from2013 to 2017. In themain part– the prospective
cohort study will enroll 2500 patients with ischemic or
non-ischemic cardiomyopathy and primary prophylactic ICD
indications for reduced LVEF according to the current
treatment guidelines. A dropout rate of 10% is expected.
Two non-randomized cohorts are established according to the
treating physician's decision and patient's preference: 1500
patients undergo primary prophylactic implantation of an ICD
at baseline (ICD group), and 750 are enrolled as control
patients which are not implanted with an ICD due to an earlier
clinical decision to go without ICD implantation strictly
unrelated to the study (Fig. 1). Mortality rates of both groupsFig. 1. Study flowchart owill be compared after adjustment for pre-specified defined
multiple confounders. In particular, it will be analyzedwhether
the presence of an ICD is a multivariate factor influencing
mortality. In addition, several ECG and Holter-based risk
markers, among them QRS- and T-wave morphology as well
as markers of autonomic tone are obtained at inclusion in order
to investigate their value to define subgroups with particularly
high or low risk of the major outcomes all-cause mortality and
appropriate ICD shock. In detail, state-of-the-art digital
analyses from the 12-lead ECG, such as QRS duration, QTc,
T-peak to T-end, early repolarization patterns, fractionation of
QRS complex and a variety of QRS complex and T-wave loop
variables as well as state-of-the-art analyses of digital
24 h-Holter-recordings for the number of PVCs, the number
and rate of non-sustained ventricular tachycardias, mean heart
rate, three selected heart rate variability parameters (standard
deviation of all intervals between normal beats, root mean
square of successive differences, low frequency heart rate
fluctuation/high frequency heart rate fluctuation), two heart
rate turbulence parameters (onset and slope) and deceleration
capacity are included. After enrollment, all patients will be
followed for at least 1 year and up to 4 years. Co-primary
endpoints are all-cause mortality and appropriate ICD shocks;
in addition, secondary endpoints are defined: time to first
inappropriate shock, death, subdivided to a) sudden cardiac
death, b) cardiac death and c) non cardiac death, respectively,
arrhythmic syncopes, resuscitations, occurrence of any ICD
shock or atrial fibrillation, costs and estimated costs, quality of
life data from several questionnaires. Furthermore, blood
samples for later genetic analyses are collected from all
patients in a biobank. The study has currently enrolled 1100
patients and expects to complete enrollment in the first half of
2017. The ICD patient's standard programming calls for
prolonged detection times to arrhythmia (12 s) and program-
mingwith a high-rate cut off (arrhythmias below a cycle length
of 300 ms are ignored).
In addition, the project also features a multicenter
European ICD retrospective registry now compiled with
4900 ICD patients from 14 of the participating centers
implanted with an ICD for primary prevention in ischemic
and non-ischemic cardiomyopathy are analyzed; first resultsf EU-CERT-ICD.
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appropriately using their ICD. Finally, meta-analyses are
performed to provide the best possible information on the
prognostic value of any marker for all-cause mortality,
appropriate shocks, inappropriate shocks, ICD revision
operations, and other complications of ICD therapy.
Danish ICDStudy inpatientswithdilatedcardiomyopathy (DANISH)
Very important in the context of a reevaluation of primary
prophylactic ICD indications, the results of the randomized
DANISH ICD study (NCT00542945) will be released in a
hotline session at the ESC congress in late August 2016.
After the publication of the SCD-HeFT results, the Danish
national treatment guidelines did not endorse primary
prophylactic ICD implantation in non-ischemic cardiomy-
opathies (they did for ischemic cardiomyopathy), but instead
entered into conducting this study. The study has random-
ized 1000 patients with dilated cardiomyopathy and an
LVEF ≤35% in a 1:1 fashion to ICD implantation and
control group without ICD implantation) between 2007 and
2014 and closed an extended follow-up in 2016.
Dutch Outcome in ICD therapy (DO-IT)
The Dutch Outcome in ICD therapy (DO-IT) trial is a
prospective multicenter registry study conducted in the
Netherlands. This study investigates the current practice of
primary prophylactic ICD therapy in the Netherlands and aims
to identify patients that do not derive benefit from ICD therapy.
Enrollment at multiple Dutch high-volume implanting centers
started in 2014 and 1500 patients are anticipated to be enrolled
in 2016 [20]. A follow-up of 1–2 years is intended.
To add to the described prospective activities in Europe,
the retrospective French Observatoire MulticentriqueFig. 2. ICD implantation per million inhabitants per EuropeFrançais Des Porteurs de Défibrillateur Automatique Im-
plantable en Prévention Primaire (DAI-PP) multicenter
registry (NCT 01992458) has enrolled 5539 patients
between 2002 and 2012, with a mean follow-up of
3.1 years. The group has published papers on the prognostic
effect of age on ICD patients [8], the effects of major risk
factors on non-arrhythmic mortality and ICD therapies, and
the effects of gender on the major outcomes mortality and
ICD therapies [21].Discussion
Current practice of ICD implantation in Europe
ICD implantation rates have substantially increased in
Europe between 2000 and 2010, with some leveling off
between 2010 and 2014 [11]. Large differences are found
between European regions and countries (Fig. 2). Disparities
may be explained by different medical infrastructures (e.g.
number of implanting centers, number of implanting
physicians) or socio-economic differences between the
individual health care system (e.g. different modes of
reimbursement). Nonetheless, variation in ICD implants
can also be seen between equally wealthy countries in
Europe. For example, a threefold higher implantation rate per
million inhabitants is reported for Germany as compared to
the United Kingdom. Thus, the phenomenon of different
ICD implantation rates between European countries is not
fully explained and probably multifactorial.
ICD benefits and risks
The net benefit of ICD therapy depends on several
factors. First, ICD systems reliably abort malignant ventric-
ular arrhythmias such as sustained ventricular tachycardiaan country (from Raatikainen [11] with permission).
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tion of this major benefit of the device thus depends on the
underlying malignant arrhythmia risk. On the other hand,
device side effects must be weighed against this expected
benefit. Electrode dysfunction, system infections, and
inappropriate therapies may contribute to potential harm
[6,12]. In patients at very low risk of life-threating
arrhythmia, these risks may outweigh the benefit; e.g. in
patients with hypertrophic cardiomyopathy, an ICD is
generally not recommended, if the risk for SCD falls
below 0.8% per year [13]. As a consequence, a large number
of patients decease without having ever received an
appropriate shock from their device [7,14]. Therefore,
accurate predictors of all-cause mortality and appropriate
ICD shocks are needed in order to improve patient selection
for prophylactic ICD therapy.Different ICD benefit in subgroups
In patients defined by a chronic LVEF ≤35%, several
publications have suggested higher or lower survival benefit
from ICD treatment in some well-defined subgroups
[10,15,16]. These subgroups need to be prospectively
investigated, since a retrospective identification is not
sufficient as proof. Recently, in a population of 3445 ICD
patients prescribed for primary prevention, Lee at al. [10]
were able to identify several subgroups at different risk of
appropriate ICD shocks using a scoring system (Fig. 3):
whereas patients in the lowest risk group revealed a
cumulative incidence of 0.9% of appropriate shock, an
incidence of 9.3% at 1 year follow-up was observed in the
highest risk group. Annual mortality ranged between 0.6%
and 17.7% in the group with the lowest and the highest risk.
Elderly patients as well as patients with co-morbidities like
kidney disease, obstructive lung disease or peripheral artery
disease revealed a high mortality risk. In general, risk scores
predicting mortality in ICD patients have been derived from
a large number of patients enrolled, a better definition ofFig. 3. Cumulative incidence of shock between differentappropriate shock is yet to be developed using various risk
stratification methods, in particular electrocardiographic
methods, such as in the EU-CERT-ICD risk stratification
study. In general, it should be noted that patients with high
mortality such as with heart failure of NYHA class IV could
potentially derive a poor benefit from their ICD while
patients with low mortality but a high proportion of
arrhythmia related sudden death may have high ICD benefit.
We have tested several ECG-based mortality and ICD
shock predictors in a series of 672 ICD patients [17]. As
presented at ESC 2015, appropriate shocks are independent-
ly predicted by VT/VF inducibility and non-negative T-wave
alternans [18]. Mortality risk did not coincide with
appropriate shock risk. Patients with very low annual
shock and mortality risks could be identified presuming
low benefit of ICD therapy, vice versa high shock risks were
also identifiable indicating higher than average ICD benefit.Study designs for ICD studies a decade after SCD-HEFT
and MADIT
For ethical reasons, new randomized trials on ICD
therapy have been deemed particularly difficult to conceive.
As an exception and because of a national decision in
Denmark, we expect the results of the DANISH ICD study to
be released at the ESC congress 2016. These will largely
supplement the ongoing discussion as to whether new study
data are necessary to adapt the ICD guidelines. Depending
on these results, discussion about randomized trials may
increase. Beyond, an observational and prospective cohort
study is the best study design possible. Results from cohort
studies identifying low risk patients could then be used in
order to conceive randomized trials in certain patient groups.
In this regard, EU-CERT-ICD study utilized a cohort study
design and further makes use of the described European
diversities that permit enrollment of true control patients
without an ICD but fulfilling guideline criteria due to
participating centers from countries with lower implantationrisk groups – from Lee et al. [10] with permission.
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to correct for the unrandomized distribution of outcome
confounders between the ICD and control groups. Further-
more, presence of the ICD can be factored into multivariate
models and its influence on all-cause mortality determined
without randomization. A prospective list of possible
confounders has been identified, hidden confounders cannot
be ruled out. Control patients in Europe, however, are not
confined to low income countries. Estimation of ICD
benefits also rests on quantifying appropriate shock rates
as a surrogate outcome of SCD. From earlier randomized
studies, it was projected that only a proportion of appropriate
ICD shocks represent truly survived SCDs [19], and a range
of 25–40% of appropriate shocks may have led to an SCD.
This number needs a reassessment soon, as researchers and
clinicians need to set a minimum risk of SCD and
appropriate shock which may be acceptable to societies not
to be treated with an ICD, for instance a 2% annual
appropriate shock rate, translating into a b1% SCD risk. It is
both possible that the number needed to treat becomes
excessively high or there is a lower end of absolute mortality
where the benefit of the ICD ends.
There is ongoing discussion whether ATP therapies should
be counted as endpoints. A number of studies report ICD
therapies as a combination of shocks plus ATP therapies,
quantitative differentiation among these is important.
EU-CERT-ICD and its preceding risk stratification study, the
EUTrigTreat clinical study [17] have chosen appropriate shock
as a major endpoint, this was also the choice in the Ontario ICD
study [9,10]. In the MADIT-RIT study [6] where programming
largely reduced the number of ATP therapies, this was neutral to
mortality. It is essential that ICD programming is kept uniform
in studies evaluating ICD benefit.Summary and outlook
The guidelines for primary prophylactic ICD treatment
have not been changed substantially for more than 10 years.
Improvements in pharmacological heart failure therapy and
interventional cardiology have been implemented in
clinical routine. As a consequence, lower mortality and
shock rates in ICD patients have been clearly observed.
These facts lead to a necessity of re-evaluation of
indications of primary prophylactic ICD therapy. Upcom-
ing prospective studies such as the EU-CERT-ICD project
aim to identify patients not deriving a benefit from ICD
therapy. LVEF alone seems no longer suitable when
decision on ICD treatment is made. The upcoming study
results could also lead to the design of randomized trials in
low risk patients.Acknowledgments
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